Literature DB >> 15644794

Thrombin-directed inhibitors: pharmacology and clinical use.

C Michael White1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15644794     DOI: 10.1016/j.ahj.2004.10.023

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


× No keyword cloud information.
  10 in total

1.  Synergistic induction of tissue factor by coagulation factor Xa and TNF: evidence for involvement of negative regulatory signaling cascades.

Authors:  Ayala Hezi-Yamit; Paul W Wong; Nga Bien-Ly; Laszlo G Komuves; K S Srinivasa Prasad; David R Phillips; Uma Sinha
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-16       Impact factor: 11.205

Review 2.  Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty.

Authors:  Ashish Shah; Dmitriy N Feldman
Journal:  Vasc Health Risk Manag       Date:  2012-02-27

3.  Crystal structure of thrombin in complex with S-variegin: insights of a novel mechanism of inhibition and design of tunable thrombin inhibitors.

Authors:  Cho Yeow Koh; Sundramurthy Kumar; Maria Kazimirova; Patricia A Nuttall; Uvaraj P Radhakrishnan; Seongcheol Kim; Pudur Jagadeeswaran; Takayuki Imamura; Jun Mizuguchi; Sadaaki Iwanaga; Kunchithapadam Swaminathan; R Manjunatha Kini
Journal:  PLoS One       Date:  2011-10-28       Impact factor: 3.240

4.  Analysis of protease activity using quantum dots and resonance energy transfer.

Authors:  Gae Baik Kim; Young-Pil Kim
Journal:  Theranostics       Date:  2012-02-01       Impact factor: 11.556

Review 5.  Bivalirudin in percutaneous coronary intervention.

Authors:  Sam J Lehman; Derek P Chew
Journal:  Vasc Health Risk Manag       Date:  2006

Review 6.  Antitumoral activity of snake venom proteins: new trends in cancer therapy.

Authors:  Leonardo A Calderon; Juliana C Sobrinho; Kayena D Zaqueo; Andrea A de Moura; Amy N Grabner; Maurício V Mazzi; Silvana Marcussi; Auro Nomizo; Carla F C Fernandes; Juliana P Zuliani; Bruna M A Carvalho; Saulo L da Silva; Rodrigo G Stábeli; Andreimar M Soares
Journal:  Biomed Res Int       Date:  2014-02-13       Impact factor: 3.411

7.  A novel hirudin derivative characterized with anti-platelet aggregations and thrombin inhibition.

Authors:  Wei Mo; Yan-Ling Zhang; Hong-Shan Chen; Long-Sheng Wang; Hou-Yan Song
Journal:  J Thromb Thrombolysis       Date:  2008-11-09       Impact factor: 2.300

8.  Prolonged High-Dose Bivalirudin Infusion Reduces Major Bleeding Without Increasing Stent Thrombosis in Patients Undergoing Primary Percutaneous Coronary Intervention: Novel Insights From an Updated Meta-Analysis.

Authors:  Gregor Fahrni; Mathias Wolfrum; Giovanni Luigi De Maria; Adrian P Banning; Umberto Benedetto; Rajesh K Kharbanda
Journal:  J Am Heart Assoc       Date:  2016-07-22       Impact factor: 5.501

Review 9.  Anticoagulation with direct thrombin inhibitors during extracorporeal membrane oxygenation.

Authors:  Barry Burstein; Patrick M Wieruszewski; Yan-Jun Zhao; Nathan Smischney
Journal:  World J Crit Care Med       Date:  2019-10-16

Review 10.  COVID-19 Associated Hypercoagulability: Manifestations, Mechanisms, and Management.

Authors:  Michael A Mazzeffi; Jonathan H Chow; Kenichi Tanaka
Journal:  Shock       Date:  2021-04-01       Impact factor: 3.533

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.